OBJECTIVE: Patients with polycystic ovary syndrome frequently suffer from hyperinsulinemia and adverse lipid profile. This study evaluated effects of metformin on lipid profile. STUDY DESIGN: Lipid profiles in hyperinsulinemic (n = 43) and normoinsulinemic (n = 45) subjects were compared. Hyperinsulinemic subjects were treated with metformin (500 mg po tid) and lipid profiles were reevaluated at 3 and 6 months of treatment. RESULTS: The hyperinsulinemic group had significantly lower high-density lipoprotein (HDL) (by 11%), higher total cholesterol to HDL ratio (by 23%), and greater triglycerides (by 57%) than the normoinsulinemic group. Six-month metformin therapy in hyperinsulinemic women was associated with a significant decrease of insulin level (by 35%), total cholesterol (by 11%), low-density lipoprotein (LDL) (by 12%), and triglycerides (by 33%). Levels of lipids in hyperinsulinemic women after metformin therapy were comparable to levels observed in normoinsulinemic subjects. CONCLUSION: The present study supports the notion that metformin may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemic women with polycystic ovary syndrome.
OBJECTIVE:Patients with polycystic ovary syndrome frequently suffer from hyperinsulinemia and adverse lipid profile. This study evaluated effects of metformin on lipid profile. STUDY DESIGN:Lipid profiles in hyperinsulinemic (n = 43) and normoinsulinemic (n = 45) subjects were compared. Hyperinsulinemic subjects were treated with metformin (500 mg po tid) and lipid profiles were reevaluated at 3 and 6 months of treatment. RESULTS: The hyperinsulinemic group had significantly lower high-density lipoprotein (HDL) (by 11%), higher total cholesterol to HDL ratio (by 23%), and greater triglycerides (by 57%) than the normoinsulinemic group. Six-month metformin therapy in hyperinsulinemicwomen was associated with a significant decrease of insulin level (by 35%), total cholesterol (by 11%), low-density lipoprotein (LDL) (by 12%), and triglycerides (by 33%). Levels of lipids in hyperinsulinemicwomen after metformin therapy were comparable to levels observed in normoinsulinemic subjects. CONCLUSION: The present study supports the notion that metformin may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemicwomen with polycystic ovary syndrome.
Authors: V Soldat-Stankovic; S Popovic Pejicic; S Stankovic; J Jovanic; J Bjekic-Macut; S Livadas; S Ognjanovic; G Mastorakos; D Micic; D Macut Journal: Acta Endocrinol (Buchar) Date: 2021 Apr-Jun Impact factor: 0.877
Authors: Zeina Haoula; Srinivasarao Ravipati; Dov J Stekel; Catharine A Ortori; Charlie Hodgman; Clare Daykin; Nick Raine-Fenning; David A Barrett; William Atiomo Journal: Metabolomics Date: 2014-08-17 Impact factor: 4.290